Inhibition of steatosis and liver fibrosis progression in patients with nonalcoholic steatohepatitis and stage two essential hypertension due to the treatment with hepadif, ezetimibe and fosinopril
JavaScript is disabled for your browser. Some features of this site may not work without it.
Inhibition of steatosis and liver fibrosis progression in patients with nonalcoholic steatohepatitis and stage two essential hypertension due to the treatment with hepadif, ezetimibe and fosinopril